Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ) closed at $15.65 on October 23, 2026, down 1.88% on the day. The stock trades 60.8% below its 52-week high of $39.89 and 22.9% above its 52-week low of $12.73. Over the past year, it lost 53.3%. Ultragenyx Pharmaceutical Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, RARE closed higher on 120 days (48%). Its best day was December 30, 2025 (+15.52%) and its worst was September 3, 2026 (-44.03%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patie...
Find more stocks like RARE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.